Coverage of our peer-reviewed research in the healthcare and mainstream press.
The American Journal of Managed Care® (AJMC®) recently held the spring 2017 ACO & Emerging Healthcare Delivery Coalition® meeting, and its coverage of the event was highlighted in Tuesday’s e-newsletter from the National Pharmaceutical Council. In a video interview with AJMC®, Clifford Goodman, senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group, explained why the shift to value-based contracts will persist despite the turbulent political climate. “There are too many other market forces in play with regard to concerns about high drug prices [and] concerns about high prices overall for a variety of healthcare services,” Goodman said.
The Thursday Daily Dose e-mail from the Academy of Managed Care Pharmacy (AMCP), highlighted an video interview with AMCP CEO Susan A. Cantrell, RPh, CAE. In the interview, Cantrell discussed policy issues that AMCP would like to see change, specifically the need to improve communication between pharmaceutical companies and payers in the pre- and post-approval settings.
Sachin Jain, MD, MBA, has been elected as a director of the Harvard Alumni Association, according to an article on IndiaWest.com. Jain, the president and CEO of CareMore, is also a member of the AJMC® editorial board. At the recent ACO Coalition meeting, he took part in a panel discussion on the social determinants of health. “We need to focus on the high costs of high-need complex patients,” Jain said. “That’s about as nonpartisan an issue as there is.”
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More